Process for preparing purine derivatives

A technology for derivatives and purines, applied in the field of preparing purine derivatives, can solve the problems of unsuitable large-scale preparation of entecavir raw materials, complicated preparation process and the like

Active Publication Date: 2007-08-15
CHIA TAI TIANQING PHARMA GRP CO LTD +1
View PDF3 Cites 11 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

However, these preparation processes are relatively complicated, requiring separation and purification conditions that are not suitable for a

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Process for preparing purine derivatives
  • Process for preparing purine derivatives
  • Process for preparing purine derivatives

Examples

Experimental program
Comparison scheme
Effect test

Embodiment Construction

[0056] 1) Preparation of Intermediate A

[0057]

[0058] Put 500ml of dry tetrahydrofuran in a 2000ml three-necked flask, and cool it to about -75°C with liquid nitrogen under the protection of nitrogen, and add 116.0g (0.68mol) of 4-methyl-benzylchloromethyl to the reaction flask ether. Put 392ml (0.69mol) cyclopentadiene sodium tetrahydrofuran solution in the balance funnel, then slowly add it dropwise into the reaction flask, control the reaction temperature at -60~-50°C, and continue to stir at this temperature for 1 hours, the intermediate A was directly used in the next reaction.

[0059] 2) Preparation of intermediate (1)

[0060] Preparation of IPC2BH

[0061]

[0062] Draw 800.0 ml (0.80 mol) of borane tetrahydrofuran solution (1.0 mol) with a syringe, and place it in an accurately weighed 250 ml two-necked round bottom flask equipped with a -80°C thermometer and a stirring bar. Under the protection of N2, cool in an ice bath to 0°C, extract 160.0ml (0.902m...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The invention discloses a making method of purine derivant with maleate monohydrate, which also provides drug composition to treat hepatitis B and/or accompanying infection.

Description

field of invention [0001] The present invention relates to a new method for preparing purine derivatives, a pharmaceutical composition containing the compound and its use for treating hepatitis B virus infection and / or concurrent infection. Background technique [0002] [1S-(1α,3α,4β)]-2-amino-1,9-dihydro-9-[4-hydroxy-3-(hydroxymethyl)-2-methylenecyclopentyl]-6H- Purin-6-one (Entecavir, Entecavir) is a new anti-hepatitis B virus drug developed by Bristol-Myers Squibb. It is a purine derivative and has a strong anti-hepatitis B virus effect. Clinically, entecavir is used to treat chronic hepatitis B in adults, including increased hepatitis virus replication activity, elevated transaminase (ATL or AST) in plasma, and active lesions in liver tissue, HBeAg positive or negative with compensated chronic liver disease. Nucleoside-naïve patients with disease, and patients who are resistant to lamivudine. [0003] US Patent Publication No. US5206244 describes entecavir, its prepara...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
IPC IPC(8): C07D473/18A61K31/522A61P31/12A61P1/16
Inventor 李志兵
Owner CHIA TAI TIANQING PHARMA GRP CO LTD
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap